Diagnostic methods using anti-MUC1* antibodies
The present application discloses a method of determining suitability of treating a patient suffering from cancer or metastasis of cancer characterized by aberrant expression of MUC1, with a MUC1* targeting therapeutic.
1. An anti-MUC1* antibody or antibody fragment comprising the following six complementarity determining regions (CDRs):
SEQ ID NOs: 144, 146, 148, 150, 152, and 154,
SEQ ID NOs: 80, 82, 84, 86, 88, and 90,
SEQ ID NOs: 112, 114, 116, 118, 120, and 122,
SEQ ID NOs: 128, 130, 132, 134, 136, and 138,
SEQ ID NOs: 160, 162, 164, 166, 168, and 170,
SEQ ID NOs: 176, 178, 180, 182, 184, and 186,
SEQ ID NOs: 192, 194, 196, 198, 200, and 202,
SEQ ID NOs: 208, 210, 212, 214, 216, and 218,
SEQ ID NOs: 224, 226, 228, 230, 232, and 234,
SEQ ID NOs: 48, 50, 52, 54, 56, and 58,
SEQ ID NOs: 64, 66, 68, 70, 72, and 74,
SEQ ID NOs: 16, 18, 20, 22, 24, and 26, or
SEQ ID NOs: 32, 34, 36, 38, 40, and 42;
wherein the six CDRs of each antibody or antibody fragment are heavy chain CDR1, heavy chain CDR2, heavy chain CDR3, light chain CDR1, light chain CDR2, and light chain CDR3, respectively.
2. The anti-MUC1* antibody or antibody fragment of claim 1 , wherein the antibody or antibody fragment comprises the following six CDRs: SEQ ID NOs: 144, 146, 148, 150, 152, and 154.
3. The anti-MUC1* antibody or antibody fragment of claim 1 , wherein the antibody or antibody fragment comprises the following six CDRs: SEQ ID NOs: 80, 82, 84, 86, 88, and 90.
4. The anti-MUC1* antibody or antibody fragment of claim 1 , wherein the antibody or antibody fragment comprises the following six CDRs: SEQ ID NOs: 112, 114, 116, 118, 120, and 122.
5. The anti-MUC1* antibody or antibody fragment of claim 1 , wherein the antibody or antibody fragment is humanized.
6. A conjugate comprising the anti-MUC1* antibody or antibody fragment of claim 1 attached to an imaging agent, a dye, a fluorescent entity, a color producing reagent or any other entity that renders the antibody or antibody fragment optically, visually, electrically or radioactively detectable.
7. A method of diagnosing cancer in a subject comprising contacting a cell or tissue of the subject with the conjugate of claim 6 .
8. The method of claim 7 , wherein the contacting is carried out in vitro.
9. The method of claim 7 , wherein the contacting is carried out in vivo.
10. The method of claim 7 , wherein the diagnosing further comprises: a) determining that: i. an amount of the antibody or antibody fragment of the conjugate of claim 6 binding to the cell or tissue is greater than an amount of the antibody or antibody fragment of the conjugate of claim 6 bound to a normal cell or normal tissue; or ii. a pattern of the antibody or antibody fragment of the conjugate of claim 6 binding to the cell or tissue is not restricted to an apical border of the cell or tissue; and b) concluding that the subject is suffering from a MUC1* positive cancer.
11. A method of determining suitability of treating a patient suffering from cancer or metastasis of cancer with a MUC1* targeting therapeutic agent comprising the anti-MUC1* antibody or antibody fragment of claim 1 , the method comprising contacting a cell or tissue from the patient with the conjugate of claim 6 .
12. The method of claim 11 , further comprising: a) determining that the conjugate binds specifically to the cell or tissue; and b) concluding that the patient is suitable for treatment with the MUC1* targeting therapeutic agent comprising the anti-MUC1* antibody or antibody fragment of claim 1 .
13. A method of treating a MUC1* positive cancer in a subject, comprising: a) determining that the conjugate of claim 6 specifically binds to a cell or tissue of the MUC1* positive cancer; and b) administering a MUC1* targeting therapeutic agent comprising the anti-MUC1* antibody or antibody fragment of claim 1 , to the subject.
14. The method of claim 13 , wherein the MUC1* targeting therapeutic agent comprises a T cell comprising a chimeric antigen receptor (CAR) comprising the anti-MUC1* antibody or antibody fragment of claim 1 .
15. The method of claim 13 , wherein the MUC1* targeting therapeutic agent comprises a bispecific T cell engager comprising the anti-MUC1* antibody or antibody fragment of claim 1 .
16. The method of claim 13 , wherein the MUC1* targeting therapeutic agent comprises an antibody drug conjugate comprising the anti-MUC1* antibody or antibody fragment of claim 1 .